Botanical Identity, Extract Specifications and Contaminant Testing

Botanical quality begins with a definition that a buyer, supplier and laboratory can use without guessing. A herb name on a label cannot describe the plant part, extraction process, carrier system or analytical evidence behind the batch. Your technical brief should connect those choices to source qualification and finished-product release. The goal is not a longer test list. It is an evidence chain that answers what the material is, what the formula contains and which risks the quality team must control.

Define identity before requesting an assay

State the accepted botanical Latin name and plant part in the purchasing specification. Include relevant synonyms in supporting records where they help reconcile supplier documents, but do not allow a commercial common name to conceal a different species. Record the form of supply: whole plant material, milled powder, dry extract or liquid preparation. A laboratory cannot select suitable identity methods without knowing how processing has changed the material.

Ask the supplier what authenticated references support its identity decision and how it handles look-alike or substituted materials. For a multi-botanical formula, define each component before discussing the blend. Triphala, for example, needs a specified constituent set and proportions rather than one umbrella name. The first-launch guide places these decisions before format and branding. A clear purchasing identity gives the quality team a basis to quarantine material that does not match the approved brief.

Qualify the source and control substitutions

Request a source specification, lot traceability description and supplier-qualification process. Ask which records link the purchased material to the approved source and what the manufacturer reviews before accepting a new vendor. Geography can inform a risk assessment, but a source story does not prove identity or safety. The reviewer needs evidence suited to the material and its handling, including what changes between harvest, extraction and receipt.

Define a substitution process in the quality agreement. Changes to species, part, extraction solvent, carrier, supplier or processing site can affect composition and the evidence required. Require the manufacturer to describe the proposed change before use, with an assessment of label, claims, analytical and stability consequences. Private label does not remove these questions; ask how the established formula controls incoming changes. For custom work, specify who has authority to approve revisions and which records the brand receives with the decision.

Read the extract specification as a whole

An extract specification should explain its starting material and relevant extraction process. Request solvent information, concentration or drying steps where relevant, carrier composition and the definition of any extract ratio. Ask whether a ratio refers to native extract or final supplied material. Without that distinction, two suppliers can report the same ratio for products with different compositions. Do not use a ratio alone to convert a raw herb quantity into a recommended serving.

Review physical characteristics that matter for the selected format, such as moisture, flow, solubility or compatibility with a liquid system. Ask which values the manufacturer controls and which are descriptive. A purchasing team should know whether a proposed alternative changes the finished formula or only a processing aid within an approved specification. The cost and MOQ guide explains why these differences must remain visible when pricing raw powders and extracts rather than disappearing inside a botanical line item.

Distinguish standardization from efficacy

Standardization sets a compositional target for named compounds under a defined method. Ask which markers the assay includes and whether the result applies to dry matter or the ingredient as supplied. A specification described as withanolides or curcuminoids can conceal differences in compound selection, calculation and sample preparation. The analytical team should explain those choices and their effect on comparison, instead of treating any matching percentage as interchangeable.

A marker assay does not prove species identity, clinical efficacy or freedom from contamination. A material can meet one marker target and still require identity and safety evidence. Do not describe a higher percentage as a better clinical outcome without product-specific substantiation and qualified review. When the formula contains several botanicals, ask how the laboratory distinguishes the chosen analytes and validates performance in that matrix. The finished-product method must answer a question about the finished product, not borrow authority from an ingredient brochure.

Choose methods that fit the matrix

Raw plants may retain anatomical features suitable for microscopy and other identity approaches. Processing can remove those features, so a dry extract needs a method or combination of methods suited to its remaining characteristics. Ask a qualified laboratory whether a chromatographic fingerprint, authenticated reference comparison or another approach supports the identity decision. The answer should state limitations as well as the evidence the method can provide.

Do not require DNA testing for every extract. Extraction and processing can degrade or remove recoverable DNA, and a result may not answer the purchasing question. Nor should a buyer assume that a single marker peak establishes botanical identity. Ask how the laboratory uses complementary evidence where one method leaves gaps. Review sample preparation, specificity and the reference materials behind the method. The presence of an instrument on a capabilities page does not establish a validated approach for your ingredient or finished blend.

Set contaminant work from product risks

Ask the quality team to assess contaminants against the material, source, process, intended serving and market. Metals deserve attention in botanical and mineral-organic materials; other questions may include microbiology, pesticides, residual solvents, mycotoxins or adulteration. A risk assessment should explain the selected work and any justified exclusions. It should not copy acceptance limits from another product or declare a universal panel adequate for every herb and format.

Have a qualified reviewer set release criteria and interpret exposure at the intended serving. Request actual results with methods, units and reporting limits where applicable. A below-reporting-limit result does not mean zero. Ask whether arsenic speciation or other targeted work is relevant, rather than asserting it belongs on every batch. Organic certification does not establish absence of metals. Shilajit needs its own identity, processing and contaminant questions because it is a mineral-organic material, not a plant that fits every botanical method.

Connect incoming evidence to finished release

An incoming extract COA identifies evidence for that ingredient lot. A finished-batch COA should identify the batch and the agreed release work for the product after manufacturing. Ask how the manufacturer maps incoming lots through weighing, blending, filling and packaging. Request the finished specification, sampling approach and handling of deviations. The buyer should know which evidence supports ingredient acceptance and which supports the decision to release the saleable product.

The manufacturer comparison places Peakfinity first for this site's ecommerce and scale-up priorities, not as an independent laboratory verdict. Use Peakfinity's herbal manufacturing information to frame project-specific requests rather than assume every listed method covers your formula. For any supplier, ask whether laboratory accreditation covers the method and scope at issue. ISO17025 concerns laboratory accreditation; it is not a blanket product certificate. FDA registration is not FDA product approval, and neither statement replaces batch evidence.

Keep the specification alive after launch

Agree how stability work supports the proposed shelf life in the selected packaging. The team should consider the formula, storage conditions, closure and changes introduced during development. Ask what evidence exists, what work remains underway and how the manufacturer manages a result that challenges the stated shelf life. A pack change may require review even when the ingredient list stays the same. Retains and storage records help the investigation if later complaints concern odor, appearance or performance.

Maintain a controlled specification and a record of approved changes. Link complaints to lot identifiers and define how the quality team investigates trends, damaged packaging or suspected contamination. Give the brand a clear contact for escalation without letting commercial staff overrule a release concern. The buyer FAQ helps align terminology, but technical approval belongs with qualified people who can explain the method, risk and evidence for the actual product. A launch does not end the supplier's qualification or the brand's responsibility to question changes.

Buyer FAQs

Does a marker percentage prove botanical identity?

No. A marker assay quantifies selected compounds under a defined method and basis. Botanical identity needs evidence suited to the species, plant part and processed matrix. Ask the laboratory how its identity approach addresses substitutions and limitations rather than accepting the assay as a substitute.

Is DNA testing suitable for every extract?

No. Processing can remove or degrade DNA and limit what a result can establish. A qualified laboratory should choose methods that fit the extract and the identity question, using complementary evidence where needed. Raw plant and processed extract methods need not be the same.

What should finished-batch evidence add to an ingredient COA?

It should link the released product batch to its agreed specification and relevant release results after manufacturing. Ask for batch identification, methods, units and deviation handling. Ingredient evidence remains part of the chain, but it does not describe all risks introduced by blending, filling or packaging.